Literature DB >> 11004723

Amplification of 9q34 in childhood adrenocortical tumors: a specific feature unrelated to ethnic origin or living conditions.

B C Figueiredo1, R C Ribeiro, G Zambetti, B Haddad, M D Pianovsky, R M Pereira, L DeLacerda, R Sandrini.   

Abstract

Adrenocortical tumors (ACT) in children under 15 years of age exhibit some clinical and biological features distinct from ACT in adults. Cell proliferation, hypertrophy and cell death in adrenal cortex during the last months of gestation and the immediate postnatal period seem to be critical for the origin of ACT in children. Studies with large numbers of patients with childhood ACT have indicated a median age at diagnosis of about 4 years. In our institution, the median age was 3 years and 5 months, while the median age for first signs and symptoms was 2 years and 5 months (N = 72). Using the comparative genomic hybridization technique, we have reported a high frequency of 9q34 amplification in adenomas and carcinomas. This finding has been confirmed more recently by investigators in England. The lower socioeconomic status, the distinctive ethnic groups and all the regional differences in Southern Brazil in relation to patients in England indicate that these differences are not important to determine 9q34 amplification. Candidate amplified genes mapped to this locus are currently being investigated and Southern blot results obtained so far have discarded amplification of the abl oncogene. Amplification of 9q34 has not been found to be related to tumor size, staging, or malignant histopathological features, nor does it seem to be responsible for the higher incidence of ACT observed in Southern Brazil, but could be related to an ACT from embryonic origin.

Entities:  

Mesh:

Year:  2000        PMID: 11004723     DOI: 10.1590/s0100-879x2000001000012

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  4 in total

1.  Virilising adrenocortical tumours in children.

Authors:  Walter Bonfig; Iris Bittmann; Susanne Bechtold; Birgit Kammer; Vera Noelle; Sissi Arleth; Klemens Raile; Hans-Peter Schwarz
Journal:  Eur J Pediatr       Date:  2003-06-14       Impact factor: 3.183

Review 2.  Genetics and epigenetics of adrenocortical tumors.

Authors:  Antonio M Lerario; Andreas Moraitis; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2013-11-09       Impact factor: 4.102

3.  The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.

Authors:  Elaine Silveira; Isadora Pontes Cavalcante; Jean Lucas Kremer; Pedro Omori Ribeiro de Mendonça; Claudimara Ferini Pacicco Lotfi
Journal:  Cancer Cell Int       Date:  2018-03-01       Impact factor: 5.722

4.  The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score.

Authors:  Ivy Zortéa S Parise; Guilherme A Parise; Lúcia Noronha; Mirvat Surakhy; Thiago Demetrius Woiski; Denise B Silva; Tatiana Ei-Jaick B Costa; Maria Helena C P Del-Valle; Heloisa Komechen; Roberto Rosati; Melyssa Grignet Ribeiro; Marilza Leal Nascimento; José Antônio de Souza; Diancarlos P Andrade; Mariana M Paraizo; Marjorana Martini R Galvão; José Renato S Barbosa; Miriam Lacerda Barbosa; Gislaine C Custódio; Mirna M O Figueiredo; Ana Luiza M R Fabro; Gareth Bond; Marco Volante; Enzo Lalli; Bonald C Figueiredo
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.